#JPM20 exclusive: Olivier Brandicourt follows the Big Pharma CEO path to private equity, joining Blackstone ahead of a mammoth fund debut

John Carroll

Editor & Founder

Nick Galakatos Blackstone

Seven months after Olivier Brandicourt’s surprise “early retirement” from Sanofi, he’s back in the game, this time taking meetings at JP Morgan to discuss his new role at Blackstone, where he’s quietly begun work with Nick Galakatos and the life sciences crew.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

#JPM20 exclusive: Olivier Brandicourt follows the Big Pharma CEO path to private equity, joining Blackstone ahead of a mammoth fund debut

John Carroll

Editor & Founder

Unlock this article instantly by becoming a free subscriber.

Despite a summer of blockbuster rounds, biotech funding is on track to level off at pre-pandemic norms

In the race to get type 1 patients off insulin, focus turns to cell transplants and insulin-producing stem cells

FDA rolls out long-awaited proposal to overhaul diagnostics regulation

FDA unveils new rare disease pilot program to increase agency-sponsor communications

Exclusive: DeepMind’s Demis Hassabis unveils his vision for Isomorphic and AI’s future in biotech

Data Quality 2.0: The Future of Real-World Evidence

#JPM20 ex­clu­sive: Olivi­er Brandi­court fol­lows the Big Phar­ma CEO path to pri­vate eq­ui­ty, join­ing Black­stone ahead of a mam­moth fund de­but

John Carroll

Editor & Founder

Unlock this article instantly by becoming a free subscriber.

De­spite a sum­mer of block­buster rounds, biotech fund­ing is on track to lev­el off at pre-pan­dem­ic norms

In the race to get type 1 pa­tients off in­sulin, fo­cus turns to cell trans­plants and in­sulin-pro­duc­ing stem cells

FDA rolls out long-await­ed pro­pos­al to over­haul di­ag­nos­tics reg­u­la­tion

FDA un­veils new rare dis­ease pi­lot pro­gram to in­crease agency-spon­sor com­mu­ni­ca­tions

Ex­clu­sive: Deep­Mind’s Demis Has­s­abis un­veils his vi­sion for Iso­mor­phic and AI’s fu­ture in biotech

Da­ta Qual­i­ty 2.0: The Fu­ture of Re­al-World Ev­i­dence

#JPM20 exclusive: Olivier Brandicourt follows the Big Pharma CEO path to private equity, joining Blackstone ahead of a mammoth fund debut

Despite a summer of blockbuster rounds, biotech funding is on track to level off at pre-pandemic norms

In the race to get type 1 patients off insulin, focus turns to cell transplants and insulin-producing stem cells

FDA rolls out long-awaited proposal to overhaul diagnostics regulation

FDA unveils new rare disease pilot program to increase agency-sponsor communications

Exclusive: DeepMind’s Demis Hassabis unveils his vision for Isomorphic and AI’s future in biotech

Data Quality 2.0: The Future of Real-World Evidence